Shanghai Funuojiansheng Biotechnology

Phonon Biopharma, officially known as Shanghai Funuojiansheng Biotechnology, is a clinical-stage biopharmaceutical company headquartered in Shanghai, China. The company focuses on the development of innovative oncolytic virus (OV) therapies designed to treat a wide range of solid tumors. Utilizing its proprietary T-01 platform, Phonon Biopharma engineers "armed" oncolytic herpes simplex viruses (oHSV) that selectively infect and destroy cancer cells while simultaneously activating the patient's immune system. Its lead candidate, T-01, has entered clinical trials for indications such as advanced solid tumors, including liver and pancreatic cancers. The company's approach aims to enhance the efficacy of existing immunotherapies by modifying the tumor microenvironment. Phonon Biopharma is supported by prominent venture capital firms and maintains state-of-the-art R&D and manufacturing facilities.